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Objective: Spinocerebellar ataxia 38 (SCA38) is caused by mutations in the ELOVL5 gene, which encodes an elon-
gase involved in the synthesis of polyunsaturated fatty acids, including docosahexaenoic acid (DHA). As a conse-
quence, DHA is significantly reduced in the serum of SCA38 subjects. In the present study, we evaluated the safety
of DHA supplementation, its efficacy for clinical symptoms, and changes of brain functional imaging in SCA38
patients.
Methods: We enrolled 10 SCA38 patients, and carried out a double-blind randomized placebo-controlled study for
16 weeks, followed by an open-label study with overall 40-week DHA treatment. At baseline and at follow-up visit,
patients underwent standardized clinical assessment, brain 18-fluorodeoxyglucose positron emission tomography,
electroneurography, and ELOVL5 expression analysis.
Results: After 16 weeks, we showed a significant pre–post clinical improvement in the DHA group versus placebo,
using the Scale for the Assessment and Rating of Ataxia (SARA; mean difference [MD]512.70, 95% confidence
interval [CI]510.13 to1 5.27, p5 0.042). At 40-week treatment, clinical improvement was found significant by both
SARA (MD512.2, 95% CI510.93 to1 3.46, p5 0.008) and International Cooperative Ataxia Rating Scale
(MD513.8, 95% CI511.39 to16.41, p5 0.02) scores; clinical data were corroborated by significant improvement
of cerebellar hypometabolism (statistical parametric mapping analyses, false discovery rate corrected). We also
showed a decreased expression of ELOVL5 in patients’ blood at 40 weeks as compared to baseline. No side effect
was recorded.
Interpretation: DHA supplementation is a safe and effective treatment for SCA38, showing an improvement of clini-
cal symptoms and cerebellar hypometabolism.
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Spinocerebellar ataxias (SCAs) are a group of autoso-mal dominant neurological disorders with a preva-
lence of 5.5 in 100,000.1 SCAs are phenotypically
characterized by gait and limb ataxia, incoordination of
eye movements, and speech disturbances. Cerebellar
hypometabolism is well documented and considered a
main diagnostic marker.2,3 More than 40 SCA subtypes
have been reported, and 34 genes have been identified so
far. Three main categories are defined on the basis of the
mutation type,4 namely those due to CAG-coding poly-
glutamine repeat expansion, noncoding repeat expan-
sions, and conventional mutations (http://neuromuscular.
wustl.edu/ataxia/domatax.html).
We recently identified SCA38 (Mendelian Inheri-
tance in Man 611805) as caused by mutations in the
ELOVL5 gene.5 The disease onset is in the fourth decade
of life, characterized by slowly progressive gait ataxia and
associated in most of the cases with pes cavus and hypo-
smia. The disease progresses with limb ataxia, dysarthria,
dysphagia, ophthalmoparesis, and, in the later stages, sen-
sory loss. Brain imaging documented cerebellar hypome-
tabolism with sparing of cerebral cortex.6
ELOVL5 encodes an elongase enzyme involved in
the synthesis of very long-chain fatty acids with a high
and specific expression in Purkinje cells.5 Its main prod-
ucts are the 22-carbon docosahexaenoic acid (DHA) and
eicosapentaenoic acid of the omega-3 polyunsaturated
fatty acid class. ELOVL5 mutations likely cause both an
altered function of the enzyme and a possible gain of
function. As a consequence, SCA38 patients have a
reduction of serum DHA, and increased ELOVL5 gene
expression and protein levels induced by transcriptional
feedback loop regulation.5
In the present work, we performed a clinical trial
on 10 SCA38 patients, and we demonstrated that oral
DHA supplementation is a safe and effective treatment,
exerting clinical efficacy and influencing cerebellar
metabolism.
Patients and Methods
Subjects
Ten subjects affected by SCA38 were evaluated at the Center
for Ageing Brain and Neurodegenerative Disorders, Department
of Clinical and Experimental Sciences, University of Brescia,
Italy. Genetic test confirmed the c.689G>T (p.Gly230Val) vari-
ant.5 Patients had already been included in a previous work on
clinical features of SCA38.6 Written informed consent was
obtained from all patients.
In the Table, patients’ demographic and clinical features
are reported. Mean age was 48.76 10.8 years, and the mean
age at onset was 38.46 6.8 years; 6 patients were females, 4
males.
The study was approved by the ethics committee of Bre-
scia Hospital, Italy (NP1821) and conformed to the Declara-
tion of Helsinki principles.
Study Drug
The study drug was a algal oil derived-DHA (Sofedus, Milan,
Italy) administered as sachets dosed at 600mg/day. Algal DHA
contains approximately 75% of DHA by weight and does not
contain eicosapentaenoic acid. The DHA dose was established
considering a meta-analysis on several reported trials.7 The
intake of 600mg/day of DHA was the highest dose employed
in the majority of the studies without side effects. DHA and
placebo sachets were indistinguishable and produced by the
same company.
Study Design
The study design is shown in Figure 1. We performed a 2-
phase trial: (1) a randomized double-blind placebo-controlled
phase of 16 weeks and (2) an open-label phase of 40-week
DHA supplementation in each patient.
Patients were initially randomly assigned (1:1) to treat-
ment with 600mg/day DHA (n5 5) or placebo (n5 5) for 16
weeks (see T0 and T1 in Fig 1).
Following the double-blind phase, all patients (n5 10)
underwent the 600mg/day DHA treatment for a total of 40
weeks (see Fig 1).
At enrollment (T0), 16-week follow-up (T1), and after
40-week DHA supplementation (T2), each patient underwent
standardized clinical assessment (ie, Scale for the Assessment
and Rating of Ataxia [SARA]8 and the International Coopera-
tive Ataxia Rating Scale [ICARS]9, brain 18-fluorodeoxyglucose
FIGURE 1: Study design. We conducted a 2-phase trial con-
sisting of a randomized double-blind placebo-controlled
phase of 16 weeks, and an open-label phase of 40-week
docosahexaenoic acid (DHA) supplementation. White bar5
placebo treatment; gray bars5DHA treatment. Black blocks
indicate the time points of clinical assessment (brain 18-
fluorodeoxyglucose positron emission tomography [FDG-
PET], electromyography/electroneurography [ENG], and
blood sampling [blood]). w5weeks.
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[FDG] positron emission tomography [PET] scan, electromyog-
raphy [EMG]/electroneurography [ENG], and blood sampling
for biological analyses).
INCLUSION CRITERIA. Inclusion criteria were: (1) symptom-
atic p.Gly230Val mutation carriers, (2) age> 18 years old, and
(3) ambulant (SARA score at baseline< 23).
EXCLUSION CRITERIA. Exclusion criteria were: (1) reported
poor compliance with drug regimen, (2) uncontrolled diabetes
(exclusion criterion to perform FDG-PET scan), (3) serum cre-
atinine levels> 2.0mg/dl, (3) alcohol abuse (equivalent
to> 12g/day) over the 30 days prior to screening, and (4) evi-
dence of drug abuse within 6 months prior to screening.
BLINDNESS. To ensure blindness in the clinical assessment
scoring, at each time point (T0, T1, and T2) neurological exam-
ination was video-recorded and analyzed blind by A.A., who
was unaware of both time point and treatment (DHA or pla-
cebo), as the videos were presented randomly. Brain FDG-PET
analyses were carried out by Statistical Parametric Mapping
(SPM), which is fully automated, unbiased, and operator-
independent software. Biological analyses were conducted by
E.D.G., N.M., and D.C. without knowledge of time point and
treatment intervention.
OUTCOME MEASURES. As primary efficacy measure, we
evaluated the significant mean change from enrollment/baseline
to endpoint on the clinical scales (SARA and ICARS). Second-
ary efficacy measures included change from baseline to end-
point on brain FDG-PET imaging and on DHA and ELOVL5
levels in blood.
SAFETY ASSESSMENTS. Safety assessments were conducted
at screening and at each visit. Adverse events were elicited by
questioning the patient throughout the study and through
direct observation by the clinical team.
Clinical Assessment, Instrumental Evaluation,
and Molecular Analyses
At each time point, videotapes of the SARA (range5 0–40)8
and the ICARS (range5 0–100)9 were employed to evaluate
cerebellar deficits. Intra-assay variability of SARA and ICARS
scores was evaluated between 2 independent neurologists (A.A.
and M.M., SARA and ICARS alpha-Cronbach5 0.983 and
0.995, respectively).
Brain PET image-processing procedures were carried out
using MATLAB (http://it.mathworks.com/products/matlab/;
MathWorks, Sherborn, MA) and SPM (http://www.fil.ion.ucl.
ac.uk/spm/software/spm12/) software. Details on image prepro-
cessing are given elsewhere.10 Cerebellar metabolism changes
were evaluated by nonparametric permutation test (10,000-per-
mutation Statistical NonParametric Mapping; T0 vs T1 and
baseline vs T2), and the threshold was set at p< 0.05, false dis-
covery rate (FDR) cluster level corrected.11
EMG and ENG were performed according to standard
procedures.
Blood sampling was performed at fast, between 8 and
9 AM. Each patient had undergone a poor-DHA diet, as recom-
mended by an expert dietician, for 2 weeks before each blood
sampling, to avoid possible confounders on blood analyses. We
measured serum DHA levels and ELOVL5 expression, as previ-
ously published.5
Statistical Analysis
Comparison of clinical characteristics between groups (placebo
vs DHA treatment) was carried out using Mann–Whitney test
or chi-square test, as appropriate. To assess the effect of DHA
treatment on clinical scores over time, in the double-blind
phase we used 2-way mixed analysis of variance (ANOVA) with
TIME (T0 vs T1) as within-subject factor and TREATMENT
(placebo vs DHA) as between-subjects factor; in the open-label
phase, we applied 1-way mixed ANOVA with TIME (baseline
vs T2) as within-subject factor. Mauchly test was used to test
for assumption of sphericity, whereas Greenhouse–Geisser epsi-
lon determination was used to correct in case of sphericity
violation.
Correlation between functional scores and demographic
or clinical characteristics was assessed using Spearman rank-
order correlations. Statistical analyses were performed using
SPSS version 21 (SPSS, Chicago, IL).
Results
Randomized Double-Blind Placebo-Controlled
Phase
No significant differences in demographic characteristics
or SARA and ICARS scores between patients who
received DHA or placebo were found. Clinical evaluation
by SARA scores of the DHA versus placebo groups after
16 weeks (T0 vs T1) showed a statistically significant
TIME3TREATMENT interaction (T0 vs T1, mean6
standard error, DHA group: 10.86 1.0 vs 7.86 0.9; pla-
cebo group: 9.76 3.2 vs 9.46 4.0; F1;85 5.88,
p5 0.042; Fig 2A).
The pre–post effect (T0 vs T1) of the DHA group
exhibited a non-null mean difference (MD) in SARA
scores (MD513.00, 95% confidence interval
[CI]511.46 to1 4.65) as compared to the placebo
group (MD510.30, 95% CI521.25 to1 1.84).
Accordingly, the TIME3TREATMENTmean difference
was non-null (3.00 2 0.30512.70, 95% CI510.13
to1 5.27).
On ICARS scores, there was also an improvement,
but not statistically significant TIME3TREATMENT
interaction (T0 vs T1, DHA group: 22.06 3.3 vs
17.06 2.5; placebo group: 20.66 8.1 vs 21.06 9.2;
F1;85 4.25, p5 0.073; see Fig 2A). The coverage interval
of the TIME3TREATMENT mean difference included
the null value (5.02[20.4]515.4, 95% CI5 -0.64
to1 11.4), although the DHA group had a non-null
pre–post effect (MD515.0, 95% CI511.37
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to1 8.63) as compared to the placebo group
(MD520.4, 95% CI524.03 to1 3.23).
In both DHA and placebo groups, no significant
differences of cerebellar metabolism at the preestablished
threshold between T0 and T1 (T0<T1) were reported.
EMG/ENG parameters were unchanged in both groups.
Serum DHA levels and ELOVL5 expression did not
show any significant TIME3TREATMENT interaction.
Open-Label Phase
Each subject underwent DHA treatment (600mg/day) in
the open-label phase for 40 weeks, and the differences
between baseline and 40-week follow-up (T2) were evalu-
ated. We found a significant improvement in clinical
symptoms, with significantly reduced SARA scores at T2
compared to baseline (baseline: 10.16 1.9, T2:
7.96 1.7; MD512.2, 95% CI510.93 to1 3.46;
F1;95 11.4, p5 0.008; see Fig 2B). The same pre–post
effect was shown for ICARS scores (baseline: 21.56 4.6,
T2: 17.96 4.2; MD513.8, 95% CI511.39
to1 6.41; F1;95 7.96, p5 0.020; see Fig 2B).
A significant difference in cerebellar metabolism
between baseline and T2 was observed, with an increase
in cerebellar metabolism at T2 as compared to baseline
in the left posterior cerebellar lobe (x, y, z5 32, 279,
223; T5 8.56; p5 0.03, cluster size5 558) and in the
right posterior cerebellar lobe (x, y, z5 22, 284, 217;
T5 7.74; p5 0.03, cluster size5 475; Fig 3). No signifi-
cant differences in the opposite contrast (baseline>T2)
were found at the preestablished threshold.
On EMG/ENG, motor and sensory conduction
velocities did not worsen during 40-week DHA
treatment.
No differences in serum DHA levels before and
after 40-week treatment were found. We showed a slight
but significant reduction of ELOVL5 expression in blood
comparing T2 with baseline (reduction to 88% from
baseline, 95% CI5 74% to 94%; F1;95 5.48,
p5 0.044).
There was no significant correlation between the
change in SARA and ICARS scores (T2 minus baseline
scores) and age, gender, age at disease onset, duration of
disease, SARA and ICARS scores at baseline, change of
ELOVL5 expression, and change of cerebellar metabolism
as measured by brain FDG-PET (Spearman rank-order
correlation, all p> 0.05).
Safety Assessment
No side effects or adverse events were reported during
DHA supplementation in either the double-blind or the
open-label phase.
Discussion
No effective treatment is currently available for most
hereditary ataxias, and management remains supportive
and symptomatic.12,13 The rationale of this study
stemmed from the observation that SCA38 is character-
ized by an increased amount of ELOVL5 protein with a
mislocalization of the aberrant form in the Golgi appara-
tus and by a decrease of its final products, in particular
DHA, in patients’ serum.5
Because ELOVL5 is strictly regulated by the
amount of arachidonic acid and DHA via a transcrip-
tional feedback loop,14 we reasoned that the administra-
tion of DHA might have exerted a double goal:
compensating the decrease of very long chain fatty acids
FIGURE 2: Clinical assessment in the double-blind random-
ized placebo-controlled phase and the open-label phase.
(A) Scale for the Assessment and Rating of Ataxia (SARA)
and International Cooperative Ataxia Rating Scale (ICARS)
scores in the docosahexaenoic acid (DHA)-treated group
and in the placebo-treated group before (T0, dark gray
bars) and after 16-week DHA/placebo treatment (T1, light
gray bars) in spinocerebellar ataxia 38 (SCA38) patients. (B)
SARA scores and ICARS scores at baseline (dark bars) and
after 40-week DHA treatment (T2, white bars) in SCA38
patients. *p<0.05.
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and lowering ELOVL5 aberrant protein.5 The endoge-
nous synthesis of DHA within the brain is low compared
with its uptake from dietary and/or liver sources.15,16
DHA is a well-known dietary supplement, well tolerated
at high dosage and with the ability to cross the blood–
brain barrier by passive and active transport.17–19
In recent years, polyunsaturated fatty acids like
DHA have gained much attention due to promising
results in a number of neurodegenerative conditions.20,21
Moreover, polyunsaturated fatty acids are required for the
normal development of the central nervous system and
their deficiency can impair cerebral function in mice.22
FIGURE 3: Improvement of cerebellar hypometabolism after 40-week docosahexaenoic acid (DHA) treatment in spinocerebellar
ataxia 38 (SCA38) patients. Pattern of cerebellar metabolism in SCA38 patients at baseline versus 40-week DHA treatment
(baseline<40-week DHA treatment, p<0.05, false discovery rate corrected). See Results for details. The results are superim-
posed on a 3-dimensional standardized template and axial magnetic resonance imaging template. L5 left; R5 right;
Z5Montreal coordinates.
TABLE. Demographic and Clinical Characteristics of Enrolled Patients according to Treatment Group
DHA Group Placebo Group
SCA38
Overall
Variable 1 2 3 4 5 6 7 8 9 10 Group,
n5 10a
Gender M M F F F F M M F F 40% M
Age at
onset, yr
38 46 35 38 36 50 44 34 37 26 38.46 6.8
Age at
evaluation, yr
46 49 51 49 39 73 47 40 58 35 48.76 10.8
SARA
score, T0
13.5 9.0 13.0 10.0 8.5 17.5 5.0 6.0 17.5 2.5 10.26 5.1
ICARS
score, T0
32.0 18.0 28.0 17.0 15.0 36.0 6.0 13.0 44.0 4.0 21.36 13.2
First
symptom
Gait
ataxia
Gait
ataxia
Gait
ataxia
Gait
ataxia
Gait
ataxia
Gait
ataxia
Gait
ataxia
Gait
ataxia
Gait
ataxia
Gait
ataxia
—
aMean6 standard deviations, otherwise specified.
DHA5docosahexaenoic acid; F5 female; ICARS5 International Cooperative Ataxia Rating Scale; M5male; SARA5 Scale for the Assessment
and Rating of Ataxia; SCA385 spinocerebellar ataxia 38; T05 time at enrollment.
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In this study, we showed that DHA supplementa-
tion ameliorates clinical symptoms and cerebellar metab-
olism in SCA38 patients. Our data are in agreement
with the hypothesis that DHA intake, acting directly on
ELOVL5 expression, reduces mutant ELOVL5 cellular
levels, as indicated by a decrease of ELOVL5 expression
in patients’ blood after 40-week DHA treatment. Fur-
thermore, a general neuroprotective effect of DHA may
occur, by promoting brain cell survival and repair
through neurotrophic, antiapoptotic, and anti-
inflammatory signaling.23 As expected, DHA administra-
tion was safe and no side effect was reported.
The rationale of our study was similar to that
described for X-linked adrenoleukodystrophy and Lor-
enzo oil treatment, the administration of which was able
to normalize very long chain fatty acids in plasma and to
provide a clinical benefit.24
We conducted the present phase II study in 2
stages. We had already demonstrated a clinical improve-
ment in the double-blind randomized placebo controlled
phase, although the low number of subjects (5 DHA vs
5 placebo) and the short-term follow-up prevented us
from reporting significant changes of cerebellar metabo-
lism and ELOVL5 expression. In the open-label phase
presented here, in which we considered the 10 patients
longitudinally, we reported significant clinical improve-
ment, especially of posture and gait, along with a marked
increase in cerebellar hypometabolism and restored
ELOVL5 expression.
We acknowledge that the small number of patients
and the lack of one of primary efficacy measure outcome
(ie, ICARS) in the double-blind placebo-controlled phase
are limitations of the study. Moreover, we did not find
any significant change of serum DHA levels before and
after treatment, and this might give rise to concerns
regarding the robustness of the effect. Larger phase III
studies addressing long-term efficacy and administration
in still asymptomatic subjects with ELOVL5 mutations
are warranted to prove DHA supplementation to be an
effective therapy for SCA38. All patients included in this
study carry the same mutation in ELOVL5. Therefore,
only the effect of DHA on this single mutation has been
assessed in this trial and generalization to all SCA38
patients is not possible, requiring further studies.
Possible benefits of DHA supplementation in other
SCAs with reduced brain fatty acids and phospholipids,
such as SCA1 and Friedreich ataxia, also need to be con-
sidered.25 Based on this observation, we may speculate
that supplementation with DHA, the main component
of brain phospholipids, might be beneficial in the early
stage of such diseases.
The treatment is a relatively inexpensive (approxi-
mately $500 per patient per year), well tolerated, and
easy to administer as a dietary intervention. We propose
that this evidence-based strategy started early in life
might delay disease onset and slow the progression of
symptoms in SCA38. Thanks to replacement treatment,
a delayed dependency in these patients may sensibly
reduce direct and indirect costs on national health
systems.
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